Morris Arlene
Transaction: 07/01/2026
BUY
Change
+32,341
Price
$18.48
Filing
07/02/2026
Type
BUY
Viridian Therapeutics, Inc.
VRDN • Biotechnology
$22.92
▼ -0.04 (-0.17%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$2.47B
Growth
-22.7%
Cash Flow
0/5
Trend
Negative
Evidence
Positive revenue growth · 35.4%Manageable debt level · 0.07Healthy liquidity · 12.65Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:00 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$22.92
Change-0.17%
Shares Out107.88M
Market Cap$2.47B
Enterprise Value$1.49B
52W Range13.18 - 34.29
Beta0.90
P/E-6.39
P/S34.76
P/B3.73
P/FCF-5.44
EV/Sales20.96
Price$22.92
Change-0.17%
Shares Out107.88M
Market Cap$2.47B
Enterprise Value$1.49B
52W Range13.18 - 34.29
Beta0.90
P/E-6.39
P/S34.76
P/B3.73
P/FCF-5.44
EV/Sales20.96
EV/EBITDA-3.82
EV/FCF-3.28
Earnings Yield-15.65%
FCF Yield-18.39%
Dividend Yield0.00%
Gross Margin100.00%
Oper. Margin-5.13%
Profit Margin-4.84%
Debt/Eq0.07
Current Ratio12.65
Quick Ratio12.65
Revenue 5Y-22.68%
Target$36.14
Target Upside57.68%
Target Median$39.00
Target Range26.00 - 43.00
Volume4.26M
Avg Volume2.50M
EPS Surprise0.16
Investment DNA
How strong this company looks for long-term investors
47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
46/100
Why this score▼
Positive revenue growth · 35.4%Manageable debt level · 0.07Healthy liquidity · 12.65Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 16 analyst votes · 2026-09-05
94/100
Bullish
Bullish
14
Hold
2
Bearish
0
Price Target
2026-08-07
Low
$26.00
Mean
$36.88
Median
$38.50
High
$45.00
Insider Transactions
Recent executive and insider activity
Kiselak Tomas
Transaction: 07/01/2026
BUY
Change
+32,341
Price
$18.48
Filing
07/02/2026
Type
BUY
Gheuens Sarah
Transaction: 07/01/2026
BUY
Change
+32,341
Price
$18.48
Filing
07/02/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Morris Arlene | BUY | +32,341 | $18.48 | 07/01/2026 | 07/02/2026 |
| Kiselak Tomas | BUY | +32,341 | $18.48 | 07/01/2026 | 07/02/2026 |
| Gheuens Sarah | BUY | +32,341 | $18.48 | 07/01/2026 | 07/02/2026 |
| Moses Jennifer K. | BUY | +32,341 | $18.48 | 07/01/2026 | 07/02/2026 |
| Ajer Jeffrey Robert | BUY | +32,341 | $18.48 | 07/01/2026 | 07/02/2026 |
| CAIN CHRISTOPHER W. | BUY | +32,341 | $18.48 | 07/01/2026 | 07/02/2026 |
| Fairmount Funds Management LLC | BUY | +1,176,470 | $17.00 | 05/11/2026 | 05/13/2026 |
| Mahoney Stephen F. | SELL | -7,408 | $30.19 | 03/03/2026 | 03/09/2026 |
| Tousignant Jennifer | SELL | -1,675 | $30.19 | 03/03/2026 | 03/09/2026 |
| Beetham Thomas W. | SELL | -3,048 | $30.19 | 03/03/2026 | 03/09/2026 |
| Harmon Seth | SELL | -2,031 | $30.19 | 03/03/2026 | 03/09/2026 |
| Mahoney Stephen F. | SELL | -7,627 | $29.32 | 03/03/2026 | 03/04/2026 |
| Mahoney Stephen F. | SELL | -18,357 | Not reported | 03/03/2026 | 03/04/2026 |
| Beetham Thomas W. | SELL | -3,138 | $29.32 | 03/03/2026 | 03/04/2026 |
| Beetham Thomas W. | SELL | -9,409 | Not reported | 03/03/2026 | 03/04/2026 |
| Harmon Seth | SELL | -2,091 | $29.32 | 03/03/2026 | 03/04/2026 |
| Harmon Seth | SELL | -6,267 | Not reported | 03/03/2026 | 03/04/2026 |
| Tousignant Jennifer | SELL | -1,724 | $29.32 | 03/03/2026 | 03/04/2026 |
| Tousignant Jennifer | SELL | -5,169 | Not reported | 03/03/2026 | 03/04/2026 |
| Tripuraneni Radhika | BUY | +19,150 | Not reported | 03/02/2026 | 03/04/2026 |